Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Medtronic, Inc. (MDT), Abbott Laboratories (ABT): Should You Trust This Top Health-Care Dividend?

The medical-device industry isn’t probably the first place you’d think to find great, high-yielding dividend stocks. While other players in health care — notably Big Pharma — offer some truly great dividends, many medical-device stocks focus more on growth and innovative products. However, income investors can’t ignore one of the industry’s largest players, Medtronic, Inc. (NYSE:MDT).

With a 2.1% dividend yield, Medtronic, Inc. (NYSE:MDT)’s not the biggest dividend stock on the block. But this company’s the world’s largest pure medical-device maker and one of the strongest players in health care. Should income investors add it to their portfolio?

The numbers line up
Medtronic, Inc. (NYSE:MDT)’s 2.1 yield might not sound like a lot, but it stands tall with some of the other major stocks in the health-care field. Abbott Laboratories (NYSE:ABT), which competes with Medtronic in the cardiovascular device space, sports only a 1.6% yield by comparison, despite being a strong pick for any income investor in its own right.

Like Abbott Laboratories (NYSE:ABT), Medtronic, Inc. (NYSE:MDT)’s also a member of the esteemed dividend aristocrats, or those companies that have raised their dividend every year for at least 25 years. Past performance may not be indicative of future results, but it’s a testament to Medtronic’s stability over the past that the company has stuck by income investors over more than two decades.

Medtronic, Inc. (NYSE:MDT)Medtronic, Inc. (NYSE:MDT) also has plenty of flexibility to boost that modest yield in the future. The company’s dividend payout ratio of just 31% — right around the S&P 500 average at the end of last year — is lower than many of the more prominent dividend stocks in health care. Abbott Laboratories (NYSE:ABT), by comparison, carries a 52% payout ratio. Unusually strong or weak earnings over the recent past can influence the payout ratio, but Medtronic’s earnings have been steady over the past three years.

But the dividend itself isn’t all there is to a strong dividend stock. Top picks for income investors also need to be steady and strong — and that’s where Medtronic, Inc. (NYSE:MDT)’s topping the charts among medical-device makers.

Growth and stability for the long run
Like many medical-device makers, Medtronic, Inc. (NYSE:MDT)’s toughed out pricing pressures and tough competition over the past few years, problems that have taken a toll on the company’s top and bottom lines. However, Medtronic’s lessened its reliance on slow-growth areas recently and focused on growing new businesses — strategies that should play out well for the long term, especially for income investors concentrated on steady growth over the coming years.

The cardiac rhythm management industry, which includes pacemakers and other cardiovascular systems, has taken an especially damaging hit of late, but Medtronic, Inc. (NYSE:MDT)’s made the best of a bad situation. In 2011, Medtronic’s cardiac disease rhythm management segment accounted for more than 32% of total sales. In the 2013 fiscal year, that number had fallen to below 30%.

Diversity makes some of the strongest health care companies — such as the aforementioned Abbott Laboratories (NYSE:ABT) — and Medtronic, Inc. (NYSE:MDT)’s in no shortage of it. While defibrillator sales have fallen, Medtronic’s grown sales of neuromodulation products, which gained 3% in the most recent quarter alone, diabetes, and surgical products strongly.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.